ALKINDI SPRINKLE

Peak

hydrocortisone

NDAORALGRANULE
Approved
Sep 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
13

Mechanism of Action

Corticosteroid Hormone Receptor Agonists

Pharmacologic Class:

Corticosteroid

Clinical Trials (5)

NCT07262957Phase 4Recruiting

Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA)

Started Sep 2025
400 enrolled
Pancreas Head CancerPancreas AdenocarcinomaIPMN, Pancreatic+7 more
NCT06895473Phase 2Recruiting

Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome

Started Jun 2025
26 enrolled
Hematopoietic and Lymphatic System Neoplasm
NCT05159284Phase 4Recruiting

Efficacy and Safety of Topical Hydrocortisone on Signs and Symptoms of Dry Eye Associated to Meibomian Gland Dysfunction

Started Nov 2021
NCT03013166N/ACompleted

THIN Database Study: Resource Use and Outcomes in Patients With Adrenal Insufficiency Prescribed Hydrocortisone: Immediate, or Modified Release, or Prednisolone

Started Sep 2016
3,000 enrolled
Adrenal Insufficiency
NCT02671058Phase 1Completed

Pharmacokinetics and Bioavailability of Hydrocortisone Acetate Suppositories

Started Mar 2016
16 enrolled
Healthy

Loss of Exclusivity

LOE Date
May 12, 2034
99 months away
Patent Expiry
May 12, 2034

Patent Records (3)

Patent #ExpiryTypeUse Code
9717740
Nov 19, 2032
U-3075
9675559
Jan 10, 2033
U-3075
9649280
May 12, 2034
Product
U-3075